Comparative Pharmacology
Head-to-head clinical analysis: CEFTAZIDIME SODIUM IN PLASTIC CONTAINER versus VELOSEF 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAZIDIME SODIUM IN PLASTIC CONTAINER versus VELOSEF 500.
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER vs VELOSEF '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis and death.
Cephradine inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis and death. It is a first-generation cephalosporin with bactericidal activity.
1-2 g IV every 8 hours for pseudomonal infections; 500 mg to 1 g IV every 8-12 hours for uncomplicated UTIs.
500 mg orally every 6 hours for 10 days.
None Documented
None Documented
1.5–2.0 hours in normal renal function; prolonged to 15–30 hours in ESRD.
Terminal elimination half-life: 1.2 hours in adults with normal renal function; prolonged to 8-15 hours in severe renal impairment (CrCl <10 mL/min); clinical context: dosing interval adjustment required for renal impairment
Primarily renal (80–90% unchanged via glomerular filtration); biliary/fecal <1%.
Renal excretion of unchanged drug: >90% (glomerular filtration and tubular secretion); biliary/fecal: <1%
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic